Huge Insider Buying in MGM and Salesforce
As the year winds down, insiders make huge buys in MGM Resorts and Salesforce. However, those were not the only notable instances of insider buying seen recently.
Headquartered in Waltham, MA Fiscal year ends December NASDAQ: VRDN viridiantherapeutics.com
Viridian Therapeutics is a commercial-stage biotechnology company focused on discovering, developing, and commercializing medicines for autoimmune and rare diseases. The company utilizes expertise in antibody discovery and protein engineering to build on proven science. Its commercial product, Lumvoa (veligrotug-vvze), is an FDA-approved full IGF-1R antagonist for the treatment of thyroid eye disease (TED). Viridian is also advancing elegrobart, a late-stage investigational subcutaneous therapy designed as a self-administered autoinjector for TED. Beyond TED, the company is developing a pipeline including an anti-TSHR antibody program for TED and Graves' disease, as well as FcRn inhibitor candidates (VRDN-008 and VRDN-006) targeting multiple serious autoimmune diseases. The company trades on Nasdaq under the ticker VRDN. Updated
As the year winds down, insiders make huge buys in MGM Resorts and Salesforce. However, those were not the only notable instances of insider buying seen recently.
Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with a company. Studies have shown that insider buys often lead…
IPOs at three biotechs last week tempted insiders to make huge purchases of shares. This effect spilled over into buying at a couple of other biotechs as well.
Recent insider buying has been highlighted by purchases by Warren Buffett, Jack Ma, Carlos Slim, and John Paulson. Biotechs tempted insiders, as did public offerings.
Viridian Therapeutics is a commercial-stage biotechnology company focused on discovering, developing, and commercializing medicines for autoimmune and rare diseases. The company utilizes expertise in antibody discovery and protein engineering to build on proven science.
The Wall Street consensus 12-month price target for VRDN is $36.75.